RBX1 and ovarian carcinoma: To confirm that the pharmacological effects of MLN4924 were due to disrupting CRL4s, we silenced RBX1 (ROC1) and CUL4A, the core component of CRL complexes, in ovarian cancer A2780 and ES-2 cells.